Unlocking Sepsis Detection: Can a Postmortem Marker Save Lives?
"New research explores TREM-1 as a potential key to diagnosing sepsis after death, offering hope for better understanding and prevention."
Sepsis, a life-threatening condition caused by the body's overwhelming response to an infection, remains a significant challenge for healthcare professionals. Early diagnosis is crucial for effective treatment, but recognizing sepsis can be difficult, especially in cases where medical history is limited or unavailable. This is particularly true in forensic settings, where determining the cause of death can be complicated by nonspecific autopsy findings.
Now, new research is shedding light on a potential breakthrough in postmortem sepsis detection. Scientists are investigating the role of Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), a protein involved in the immune response, as a reliable marker for identifying fatal sepsis cases after death. This research offers hope for improving diagnostic accuracy and gaining a better understanding of sepsis-related mortality.
This article delves into a study that explores the potential of TREM-1 as an immunohistochemical marker for postmortem diagnosis of sepsis. We'll examine the study's methodology, findings, and implications for the future of sepsis detection and management. By understanding how TREM-1 expression differs in sepsis-related deaths, researchers aim to provide a valuable tool for forensic pathologists and potentially inform clinical strategies for combating this deadly condition.
TREM-1 as a Sepsis Biomarker
Soluble TREM-1 (sTREM-1) has been reported at increased levels in patients with sepsis, and one study tested whether serum levels rise early in sepsis and fall afterward. Research into TREM-1’s diagnostic and prognostic potential continues, including a prospective cohort study of newborns with late-onset neonatal sepsis published in 2026. A 2022 review noted that the evidence on neonatal sepsis is limited by the small number of clinical studies, regional bias, and differences in detection methods, and called for larger, higher-quality studies.
From Immune Receptor to Sepsis Target
A 2001 Lancet commentary described sepsis as a dysregulated host response to microbial components, including lipopolysaccharide from gram-negative bacteria and peptidoglycan or extracellular toxins from gram-positive bacteria. It noted that exposure to lipopolysaccharide activates neutrophils and monocyte/macrophages, prompting release of proinflammatory cytokines. TREM-1 is a pattern-recognition receptor whose activation can promote cytokine and chemokine release and increase its own expression, including circulating cleaved soluble TREM-1. By 2022, reviews described TREM-1 modulation as a promising strategy for developing sepsis treatments.
TREM-1: A Beacon in the Fight Against Sepsis?
TREM-1 is a protein that amplifies the inflammatory response to bacterial and fungal infections. Because TREM-1 is strongly expressed on phagocytes that accumulate in inflamed areas, scientists hypothesized that it could serve as a valuable marker for identifying sepsis even after death. The study focused on analyzing TREM-1 expression in various tissues of individuals who died from septic shock.
- Lung Tissue: Immunostaining was observed in cells of the monocyte line in 24 out of 28 cases, suggesting that TREM-1 production is primarily driven by these cells.
- Liver Tissue: Low TREM-1 staining was found in the hepatocyte cytoplasm, duct epithelium, portal-biliary space, and blood vessels.
- Kidney Tissue: TREM-1 antibody immunostaining was detected in glomeruli and renal tubules, as well as in the lumen of blood vessels.
- Control Group: No TREM-1 reaction was observed in organs or blood vessels of individuals who died from non-infective causes.
Limits of Postmortem sTREM-1 Testing
A review of postmortem sepsis investigations concluded that sTREM-1 alone was not better than procalcitonin (PCT) or C-reactive protein (CRP) for diagnosing sepsis in forensic settings. The review also reported that pericardial fluid, unlike urine, could be a valid alternative to serum when blood samples are insufficient or unavailable. Separately, a systematic review identified at least 122 microRNAs and signaling pathways involved in sepsis-related organ dysfunction.
Interpreting TREM-1 Changes
TREM-1 is expressed on neutrophils and monocytes, is upregulated in sepsis, and appears to tune the inflammatory response, according to a 2014 study. That study explored TREM-1 expression at the gene level and on cell membranes, underscoring that its measurement involves distinct forms of expression. A separate whitepaper presents TREM-1 as a promising prognostic biomarker, but the supplied summary does not provide study results or performance figures to establish its clinical reliability.
Different Markers, Different Evidence
The supplied studies address different settings and markers, so they do not establish a direct head-to-head comparison involving postmortem TREM-1. One study examined p53 protein expression by immunohistochemistry in tissue samples from 36 patients with cholangiocarcinoma, while another found p53 expression in 19 cases of lung carcinoma using the DO-7 antibody. A Warthin tumor study analyzed 24 cases using CK7, CK5/6, CK19, and p63 antibodies. A 2025 report says its biomarkers were more effective at identifying updated sepsis than clinical scores, but the supplied snippet does not name the biomarkers or give comparative accuracy figures.
Implications and Future Directions
This research provides a foundation for further exploration of TREM-1 as a postmortem diagnostic tool for sepsis. While the study demonstrates promising results, it also acknowledges limitations, such as the relatively small sample size and the lack of comparison with other immunohistochemical studies. Future research should focus on expanding sample sizes, comparing TREM-1 expression with other sepsis biomarkers, and investigating the potential role of TREM-1 in non-infective inflammatory diseases.
Toward Earlier, More Personalized Sepsis Care
A 2026 review argues that combining advanced omics with accessible diagnostics could help advance sepsis care toward earlier detection, personalized treatment, and better patient outcomes. The article described in the supplied material focuses on a study of TREM-1 as an immunohistochemical marker for postmortem sepsis diagnosis, examining how expression differs in sepsis-related deaths. The source summary frames this work as a potential tool for forensic practice and future sepsis detection and management.
TREM-1 Findings Across Patients and Cases
In a study of septic patients, monocyte TREM-1 expression was significantly lower at the severe sepsis or shock stage than at the sepsis stage among patients with Gram-negative community-acquired infections or polymicrobial infections. The study also reported this pattern in severe sepsis or shock associated with ventilator-associated or hospital-acquired pneumonia. In a separate postmortem investigation, researchers tested an anti-TREM-1 antibody in 28 deaths from septic shock and divided the cases into two groups; the supplied summary says diagnoses followed Surviving Sepsis Campaign criteria.
Ultimately, the goal is to refine and validate the use of TREM-1 as a reliable and readily available marker for postmortem sepsis diagnosis. This could have significant implications for forensic investigations, public health monitoring, and clinical strategies for preventing and managing sepsis.
By improving our ability to identify sepsis-related deaths, we can gain valuable insights into the epidemiology of this condition, inform strategies for early detection and treatment, and ultimately save lives. The investigation of TREM-1 as a postmortem marker represents a significant step forward in the ongoing fight against sepsis.